Fig. 3From: A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary diseaseChange from baseline in serial FEV1 on Day 1 (a) and Day 28 (b). Data presented as LS mean ± SE. Abbreviations: FEV1: forced expiratory volume in 1 s; h: hours; LS: least squares, Rev.: revefenacin; SE: standard errorBack to article page